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A Ab bs st tr ra ac ct t
Advances in human genomics are ushering in a new era of predictive, preventative and
personalized approaches to medicine. However, as the integration of genomic medicine
progresses, the health community has a responsibility to communicate to the public the risks and
challenges of genetic information. A possible knowledge transfer framework is outlined as a
means to bridge the practical uses of genetics within various ethical, social and economic
contexts. Tools and resources are needed to help clinicians understand genetic risks and help
them inform the public appropriately and effectively.
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I In nt tr ro od du uc ct ti io on n
After decades of identifying genes involved in single gene
diseases, large-scale genotyping technologies with one
million single nucleotide polymorphisms per sample now
enable the association and identification of genes involved in
complex diseases. Genome-wide association studies identify
hundreds of commonly occurring gene variants that are
thought to result in an increased risk for some common
complex conditions such as type I/II diabetes, Crohn’s disease,
coronary artery disease and several forms of cancers.
Furthermore, developments such as expression arrays allow
the identification of genes that are active in normal and
diseased cells. These advances in human genomics are
ushering us into a new era of predictive, preventive and
personalized approaches to medicine. Hopefully, this will
allow individuals to use their genetic information to avoid or
minimize the risk of serious disease, to adopt preventive
strategies to cope with common chronic conditions, and to
have their medical care targeted to their genetic profile and
tailored to their needs [1]. It is thus expected that health
professionals of various specialties will face increasing
demands to integrate genomic medicine into their practices,
and challenges that include recognizing patients who
should be referred for genetic testing, ordering and
interpreting tests, communicating risk information,
promoting prevention strategies, providing advice to
patients about the meaning of genetic variations,
prescribing drugs and responding to patients seeking
information after receiving direct-to-consumer (DTC) test
results [2].
This raises questions about whether physicians and other
health professionals are prepared to respond to these
challenges and whether they have adequate knowledge about
modern genetics and genomics [3]. Most physicians have no
formal training in genetics, and currently little research has
focused on their understanding of the recent developments
in genomics [4,5]. It is unclear how physicians will handle
genetic test results, address uncertainty associated with the
lack of therapeutic intervention, evaluate and communicate
positive or negative results (especially when the test has a
limited ability to predict whether the gene variant will result
in disease), translate population screening statistics into
individual information for a patient, and/or react to possiblebiases in the popular press or from an overenthusiastic
scientific community [6]. In addition, how will the physician
address concerns about the possible impact of positive
genetic results within families, or the possible disclosure of
the genetic information to third parties? Also, while public
demand for gene testing appears to be increasing, there are
concerns about a lack of public understanding of the
complex genomic information and the potential social harms
associated with the disclosure of genetic information [7].
D Di is sc cu us ss si io on n
I In nt te eg gr ra at ti in ng g   g ge en no om mi ic c   m me ed di ic ci in ne e   i in nt to o   t th he e   c cl li in ni ic c
A recent review of the literature has concluded that,
currently, there are few models for integrating genomic
medicine for common diseases into primary care. Moreover,
front-line health professionals are not confident of their
genomics/genetic knowledge. Patients are ill-informed and
seem to have inflated expectations about the value of genetic
testing. Finally, there is little scientific evidence regarding
the clinical utility of genomic interventions [8].
While reliable scientific evidence is needed, the knowledge
generated in a research laboratory is almost never ready for
transfer to the clinic, partly because of the lack of integrative
approaches. As McBride et al. point out [1], it is important to
incorporate various perspectives into research projects
studying the integration of genetics/genomics into clinical
practice. A knowledge transfer framework developed by
Landry [9] presents a useful outline for understanding the
values and beliefs expressed by patients and health
professionals to help guide the process of knowledge transfer
so that, for example, systematic reviews and guidelines
match the reality and expectations of the end users. The
framework seeks to identify, create, transform and transfer
knowledge while paying particular attention to various legal,
ethical, social and economic contexts. The four phases of the
framework address: (1) identification of knowledge-based
opportunities, (2) transformation of knowledge-based oppor-
tunities into new or improved products, services and
practices, (3) communication of the developed knowledge
within an organization or with other organizations and (4)
application of the value of the communicated knowledge.
Value is created when the quality of products or services has
been improved, for example at the level of health and safety,
profitability, ease of use and so on.
H He ea al lt th h   p pr ro of fe es ss si io on na al ls s’ ’   u un nd de er rs st ta an nd di in ng g   o of f   g ge en no om mi ic c   i in nf fo or rm ma at ti io on n
While geneticists play a key role in the delivery of genetic
and genomic medicine of single gene disorders, the integra-
tion of genomics for common diseases will give more
responsibilities to other healthcare professionals. This is
especially so within the primary healthcare field where
family doctors are expected to play a key role. Yet, providing
risk information on complex diseases remains a major
challenge. An exercise carried out during the 2006 National
Coalition for Health Professional Education in Genetics
(NCHPEG) meeting in Bethesda illustrates the difficulty
with interpreting genetic risk information. Each attendee
received a name tag with a risk estimate of obtaining a
disease and was labelled as either having a 96% chance of
being unaffected with a disorder, a 1 in 25 chance of being
affected, or a 4% chance of being affected. The attendees
were asked to choose whether they were in a high-, moderate-
or low-risk group. Three distinct groups formed in the
lecture hall, indicating that most genetic professionals failed
to recognize that they were all in the same low-risk group
[10]. This shows that development of new tools and educa-
tional approaches is needed to help clinicians understand
the concepts of genetic risk more effectively.
Additionally, no more than 3% of published clinical research
in genomics moves beyond the initial phase of basic genome-
based discovery into a health application (for example, risk-
assessment strategies, decision or patient management) [11].
This number is disappointingly low, but this gap is being
redressed by the Evaluation of Genomics Applications in
Practice and Prevention (EGAPP) Working Group, set up by
the Centers for Diseases Control and Prevention (CDC).
EGAPP aims to evaluate evidence, and to assess genetic tests
and other genomic applications as they are being introduced
into the clinical or public health environment. EGAPP
reviews will provide guidance on the appropriate use, for
example, of genetic tests in the clinic [12]. There will be a
need for large clinical studies to identify risk factors involved
in health and illness of large populations, which, needless to
say, will require additional funding and a close collaboration
between all health professionals to accelerate the translation
of these discoveries and to help narrow the gap between
bench and bedside.
P Pu ub bl li ic c   u un nd de er rs st ta an nd di in ng g   a ab bo ou ut t   g ge en no om mi ic c   i in nf fo or rm ma at ti io on n
The public’s knowledge of genomics is low but their attitude
toward genomic medicine is generally positive [13]. DTC
genomic testing further intensifies the need for enhanced
educational initiatives, as the public will require additional
knowledge and resources in order to make informed choices
in relation to their genetic “profile” being seemingly predic-
tive of future illnesses [14]. For example, some patients
overestimate their own risk or have difficulty understanding
that a breast cancer gene mutation can be carried by a male.
For some, it is not inconceivable that genetics may push
patients to adopt a deterministic attitude or “genetic
fatalism” following the disclosure of their risk status.
Increasingly, family doctors are reporting that their patients
are likely to be interested in the genetic causes of the disease
and the potential benefits of genetic testing.
E Ed du uc ca at ti io on n   t to o   i im mp pr ro ov ve e   h he ea al lt th h   p pr ro of fe es ss si io on na al ls s’ ’   a an nd d   p pu ub bl li ic c’ ’s s
k kn no ow wl le ed dg ge e   a ab bo ou ut t   g ge en ne et ti ic cs s
Given the rapid pace of genomics research, health profes-
sionals will require access to continuing medical education
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example of such an initiative is provided by the NCHPEG, an
interdisciplinary group of diverse health professional
organizations, consumer groups, and private and govern-
mental organizations that provides resources to integrate
genetic information into all levels of professional education
[15]. Educational resources for the public have been
developed by governmental organizations such as the CDC
[16], and via policy databases by non-governmental groups,
including HumGen International [17].
Many international organizations also support community
engagement to facilitate the educational process for the
public. The public expects to know more about what is going
on, and wants to be active in matters of scientific policy
making and research [18]. However, enabling public engage-
ment is complex, costly, and raises a number of practical
questions, including just who the public is (for example,
individuals or groups, patients, stakeholders?), what
approaches are the most effective (for example, consultation,
partnership, public deliberations?), and how the impact and
contributions of different models of public engagement can
be evaluated and compared. The field of genetics is changing
the way health care is practiced. In addition, as the public
hears more and more about genetics, health professionals
will need to know how to answer the questions asked by
their patients. However, health professionals have not
always kept up to date with the genetic advances, let alone
with the ethical and professional challenges. For example,
patients have concerns about the usefulness of the risk
information, how genetic information can affect insurance
and how it will impact on their family and on their children
[19]. To meet these challenges, there has to be a corres-
ponding increase in efforts to improve medical education, in
particular by placing genetics, genomics and risk assessment
into the core medical curriculum.
C Co on nc cl lu us si io on ns s
Recent genomics-related discoveries and biotechnological
progress are impressive and hold much clinical promise.
There is, however, a relative paucity of evidence on how
health professionals are or ought to be incorporating
genomics into the delivery of care. There is thus also a
pressing need for greater attention to the design and conduct
of integrated evaluative research, particularly with regard to
risk communication. There is a similar need for an
expansion of professional training programs and public
education and engagement initiatives in which the social,
ethical, scientific and policy implications of advances in
genomics are discussed in a transparent and forthright
manner. In the spirit of the White Papers that have been
launched by the National Human Genome Research
Institute [5,7,20], we hope by this commentary to stimulate
further interest in these pressing issues, and invite both
health professionals and the public to contribute their views.
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